ROCKET PHARMACEUTICALS, INC. - 8-K Filing
Rocket Pharmaceuticals aligned with FDA on continued enrollment and dosing for pivotal Phase 2 trial of RP-A501 in Danon disease, including a recalibrated dose and 12-patient population. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $RCKT